comparemela.com

Page 4 - Mark Bleackley News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Incannex Healthcare gains ethics green light for Phase 2 clinical trial assessing IHL-675A as rheumatoid arthritis treatment

Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) is preparing to advance its clinical trial assessing the treatment of rheumatoid arthritis to the second.

Date: July 13, 2023 Public Announcement (NASDAQ

Incannex Receives HREC Approval For Phase 2 Clinical Trial Of CBD-Based Drug For Use In Treatment Of Rheumatoid Arthritis - Incannex Healthcare (NASDAQ:IXHL)

Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL) has received approval from Bellberry Human Research Ethics Committee (‘HREC’) for the lead site, Emeritus Research, Camberwell, Victoria, for its phase 2 clinical trial.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.